| Document |
Document Title |
|
WO/2021/138443A1 |
Methods and compositions for modifying the course and severity of neuropsychiatric disorders. The method includes administering a composition to a subject suffering from a neuropsychiatric disorder, wherein the composition includes a sub...
|
|
WO/2021/134086A1 |
Provided herein are arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders.
|
|
WO/2021/105356A1 |
The invention concerns new keto-ammonium compounds with surfactant properties and improved biodegradability.
|
|
WO/2021/103728A1 |
An organic compound and an organic electroluminescent device using the compound used for the field of organic electroluminescence. The organic compound is as shown in structural formula I, wherein Ar1 to Ar 4 are independently selected f...
|
|
WO/2021/101867A1 |
The disclosure provides salts of (2R,6R)-hydroxynorketamine (HNK), wherein the salt is with an organic acid chosen from malonic acid, salicylic acid, ethane sulfonic acid, glycolic acid, stearic acid, or capric acid, and their crystal fo...
|
|
WO/2020/251015A1 |
Provided is a method for producing a substance related to 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione that is suitable for industrial production. The present disclosure provides: a method for producing two production intermediates for 2...
|
|
WO/2020/237749A1 |
Provided is a compound having a long-acting therapeutic effect. The compound can be used to prepare an antidepressant drug and drugs for anesthesia, analgesia, improvement of cognitive function, lung protection, amyotrophic lateral scler...
|
|
WO/2020/239942A1 |
The invention relates to 1,4-diaminoanthraquinones and an electrolyte, and their use in batteries.
|
|
WO/2020/237748A1 |
Provided in the present application is a method for preparing a compound having a long-acting therapeutic effect. The compound may be used to prepare antidepressant, anesthetic and analgesic drugs, as well as drugs for cognitive function...
|
|
WO/2020/232274A1 |
Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.
|
|
WO/2020/227168A1 |
The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with th...
|
|
WO/2020/215388A1 |
Provided are a deep red light thermally activated delayed fluorescence material, a preparation method therefor, and an electroluminescent device. The deep red light thermally activated delayed fluorescence (TADF) material comprises a com...
|
|
WO/2020/212510A1 |
The present invention is directed to methods for the asymmetric synthesis of esketamine. The present invention is further directed to key intermediates in the asymmetric esketamine synthesis. In one embodiment, the invention is an asymme...
|
|
WO/2020/212157A1 |
The invention concerns a new, efficient process for the preparation of enantiomerically pure norepinephrine (also known as noradrenaline), or an addition salt thereof, using a catalytic hydrogenation system under hydrogen donor transfer....
|
|
WO/2020/212399A1 |
The present invention relates to a method for the preparation of the preparation of ethyl (2S, 3S)-3-aminobicyclo [2.2.2] octane-2 -carboxylate from the β-keto ester (II) via a chiral transfer hydrogenation reaction in the presence of a...
|
|
WO/2020/212890A1 |
Disclosed herein is a method for synthesizing levomethadone hydrochloride including producing (R)-2-(dimethylamino)propan-1-ol by reducing Ν,Ν-dimethyl-D-alanine using borax, forming (R)-1-chloro-N,N-dimethylpropane-2-amine hydrochlori...
|
|
WO/2020/192348A1 |
Disclosed are phenyl allylidene cyclohexenone derivatives with the structure shown in general formula I. In combination with structural characteristics and structure-function relationship of piplartine, amino bonds are replaced with doub...
|
|
WO/2020/187155A1 |
Use of an apocynin dimer analogue derivative in preparing a medicament or a health care product for preventing and treating Parkinson's disease. The structure of the apocynin dimer analogue derivative is as shown in formula I. The apocyn...
|
|
WO/2020/172749A1 |
Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as metho...
|
|
WO/2020/169054A1 |
The present invention relates to crystalline forms I and II of a (E)-α,β-unsatured amide compound, preparation methods therefor, and uses thereof. The crystalline forms all have excellent properties in physical and chemical stability a...
|
|
WO/2020/163612A1 |
Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the ...
|
|
WO/2020/159587A1 |
Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The stru...
|
|
WO/2020/037372A1 |
A method of detecting the presence of an NBOMe in a sample which comprises of contacting the sample with an activated p-quinone such as 2,3,5,6-tetrachloro-1,4-benzoquinone (TCBQ) and an aldehyde, for example acetaldehyde, and optionally...
|
|
WO/2020/008051A1 |
The present invention relates to a compound of the following formula (I): (I). The invention also relates to uses thereof as dye or pigment, notably as a luster pigment,and to areflective or photonic or nanophotonic or optoelectronic dev...
|
|
WO/2020/003022A1 |
Described are polymerizable high energy light absorbing compounds of formula I: Wherein Y, Pg, R1, R2, R3, R4, R5, and R6 are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light a...
|
|
WO/2020/002338A1 |
A process for the continuous production of a reaction product of a diazo‐compound and a substrate in a multi‐stage flow reactor is disclosed.
|
|
WO/2019/236557A1 |
A process for the preparation of (2R,6R)-hydroxynorketamine is provided. The process requires no chromatography purification and affords the (2R,6R)-hydroxynorketamine in eight steps with a 26% overall yield and greater than 97% purity.
|
|
WO/2019/223015A1 |
Disclosed are a precursor for a blue anthraquinone active disperse dye and a preparation method therefor. A parent body structure of the precursor is of an anthraquinone structure, has an amino capable of being reacted with an active gro...
|
|
WO/2019/223016A1 |
Provided are a blue anthraquinone active disperse dye suitable for use in a supercritical CO2 fluid dyeing process and a preparation method therefor. A parent structure of the active disperse dye is of an anthraquinone structure, and als...
|
|
WO/2019/219942A1 |
Provided is a process for producing an amine via a hydroaminoalkylation reaction of a non-aromatic C-C double bond or C-C triple bond, said process comprising a step of reacting a compound comprising a non-aromatic C-C double bond or C-C...
|
|
WO/2019/213551A1 |
The disclosure provides a method of treating a substance use disorder in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising R(-)-ketamine or a pharmaceutically acceptable sal...
|
|
WO/2019/199518A1 |
Processes are disclosed for synthesizing an α-amino acid or α-amino acid derivative, from a starting compound having a carbonyl functional group (C=O), with hydroxy-substituted carbon atoms at alpha (α) and beta (β) positions, relati...
|
|
WO/2019/192602A1 |
The present invention relates to an aromatic compound and a preparation method therefor and the use thereof. Specifically, disclosed are a compound as shown in the following general formula (I), or a tautomer, an enantiomer, a diastereom...
|
|
WO/2019/189110A1 |
A photosensitive resin composition, a cured film, a laminate, a method for manufacturing a cured film, and a semiconductor device, in which: a heterocycle-containing polymer precursor, a thermal base generator, and a radically polymeriza...
|
|
WO/2019/178677A1 |
The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery...
|
|
WO/2019/181714A1 |
A compound according to the present invention is characterized by being represented by formula wherein: R1 represents an oxygen atom or a sulfur atom; and each of R2-R6 independently represents a hydrogen atom, an alkyl group having 1-6 ...
|
|
WO/2019/169504A1 |
We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP ...
|
|
WO/2019/129815A1 |
The invention provides a method for synthesizing a compound of formula (I) wherein each R independently represents an optionally substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy, acyl, carboxyl, hydroxyl, ...
|
|
WO/2019/122204A1 |
Disclosed are processes for the manufacture of pyrazole compounds of formula (I) and their application in the manufacture of pyrazole derivatives, in particular in processes for the manufacture of pharmaceutically or agrochemically activ...
|
|
WO/2019/122400A1 |
The present invention relates to the application of biosynthetic engineering for the heterologous expression of a gene cluster for the biosynthesis of tetracycline compounds, notably chelocardin and its analogues. More particularly, the ...
|
|
WO/2019/108800A1 |
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.
|
|
WO/2019/077332A1 |
The present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein ≃ is selected from a single bond and a double bond, wherein ≃ is 1, 2 or 3, wherein R1, R2, R3, R4, R5, and R6 are each se...
|
|
WO/2019/073408A1 |
The invention provides an oral extended release formulation for the treatment of treatment- resistant depression, treatment-resistant anxiety, and phobia.
|
|
WO/2019/071355A1 |
Described are methods and products related to the identification of multiple sclerosis (MS) as a transmissible protein misfolding disorder. Data is presented to support the position that the transmissible protein is an abnormal prion pro...
|
|
WO/2019/047846A1 |
Derivatives of hypocrellin with peri-position and 2-position simultaneously substituted by amino groups and a preparation method and application thereof are disclosed. The structural formula of the derivatives is as shown in the formulae...
|
|
WO/2019/042301A1 |
The present invention provides a new class of (E)-α,β-unsaturated amide compounds represented by formula I, and also relates to methods for preparing such compounds and the pharmaceutical uses thereof. The compounds have the effect of ...
|
|
WO/2019/035775A1 |
A method for the preparation of tapentadol in the form of a base or its hydrogen chloride, which involves the preparation of a salt (III) from a mixture of diastereomers (II) by means of crystallization-induced asymmetric transformation ...
|
|
WO/2019/036678A1 |
Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
|
|
WO/2018/227300A1 |
Novel urea, thiourea and squaramide compounds and bioisosteres thereof of formulas (I) and (VI) and the use thereof for treating, attenuating, inhibiting or preventing inflammation and inflammation-related pathologies are described herein.
|
|
WO/2018/212368A1 |
The present invention relates to a novel compound and a pharmaceutical composition, for preventing or treating degenerative neurological disorders, comprising the compound as an active ingredient. The novel compound, which is obtained by...
|
